Published in Nat Commun on June 25, 2014
Rho GTPase signalling in cell migration. Curr Opin Cell Biol (2015) 1.38
Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol (2015) 1.14
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci Rep (2015) 0.91
TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. Curr Biol (2015) 0.90
Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination. J Natl Cancer Inst (2015) 0.89
Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget (2016) 0.82
Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation. Oncotarget (2015) 0.80
Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. Sci Rep (2015) 0.78
Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin. Nat Commun (2017) 0.78
Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. Oncoimmunology (2015) 0.77
Roles of paxillin family members in adhesion and ECM degradation coupling at invadosomes. J Cell Biol (2016) 0.76
Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget (2016) 0.76
Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer (2016) 0.76
Extracellular microvesicles and invadopodia mediate non-overlapping modes of tumor cell invasion. Sci Rep (2015) 0.76
Modes of invasion during tumour dissemination. Mol Oncol (2016) 0.76
Reactive oxygen species and tumor dissemination: Allies no longer. Mol Cell Oncol (2016) 0.75
Matrix metalloproteinase-9 expression is enhanced in renal parietal epithelial cells of zucker diabetic Fatty rats and is induced by albumin in in vitro primary parietal cell culture. PLoS One (2015) 0.75
Rho, ROCK and actomyosin contractility in metastasis as drug targets. F1000Res (2016) 0.75
ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med (2016) 0.75
S100A4 elevation empowers expression of metastasis effector molecules in human breast cancer. Cancer Res (2016) 0.75
MiR-211/STAT5A Signaling Modulates Migration of Mesenchymal Stem Cells to Improve its Therapeutic Efficacy. Stem Cells (2016) 0.75
The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity. Mol Biol Cell (2016) 0.75
Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells. Onco Targets Ther (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci U S A (1997) 19.46
Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer (2003) 13.01
Genomic analysis of metastasis reveals an essential role for RhoC. Nature (2000) 10.11
CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 9.13
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol (2003) 7.93
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol (2003) 7.89
Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol (2009) 7.77
Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J (2004) 7.62
Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol (2007) 7.20
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature (2007) 7.05
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol (2007) 6.15
Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01
Plasticity of cell migration: a multiscale tuning model. J Cell Biol (2009) 5.82
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem (1989) 5.64
Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol (2001) 4.99
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 4.93
Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol (2009) 4.39
Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol (2009) 4.04
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol (2006) 3.55
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics (2008) 3.11
Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol (2009) 3.09
Myosin phosphatase: structure, regulation and function. Mol Cell Biochem (2004) 3.02
Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol (2005) 3.02
CD44 in cancer. Crit Rev Clin Lab Sci (2002) 2.83
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (2002) 2.75
A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes. Nat Cell Biol (2013) 2.59
CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. Eur J Immunol (1998) 2.28
PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol (2008) 2.27
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta (2011) 2.22
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood (2008) 1.98
The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med (2010) 1.84
Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventions. Nat Cell Biol (2013) 1.84
DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol (2008) 1.75
Extracellular matrix controls myosin light chain phosphorylation and cell contractility through modulation of cell shape and cytoskeletal prestress. Am J Physiol Cell Physiol (2004) 1.68
The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. J Neurosci (2008) 1.60
N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J Cell Biol (2012) 1.45
Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell (2010) 1.39
Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol (2012) 1.38
Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem Soc Symp (2003) 1.37
An ezrin-rich, rigid uropod-like structure directs movement of amoeboid blebbing cells. J Cell Sci (2011) 1.28
Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci (2011) 1.27
Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J Neurosci (2008) 1.23
Tumor cell migration in three dimensions. Methods Enzymol (2006) 1.18
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer (2011) 1.18
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood (2003) 1.18
RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation. Nat Cell Biol (2011) 1.17
Rho-kinase regulates energy balance by targeting hypothalamic leptin receptor signaling. Nat Neurosci (2012) 1.10
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups. Bioorg Med Chem Lett (2001) 1.02
The metastasis gene NEDD9 product acts through integrin β3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci (2012) 1.01
MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal (2011) 1.01
The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer (2009) 0.99
Rho GTPase signaling modulates cell shape and contractile phenotype in an isoactin-specific manner. Am J Physiol Cell Physiol (2003) 0.96
Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia (2011) 0.95
Early elevation of matrix metalloproteinase-8 and -9 in pediatric ARDS is associated with an increased risk of prolonged mechanical ventilation. PLoS One (2011) 0.94
RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem (2004) 0.91
Constitutive secretion of MMP9 by early-passage cultured human endothelial cells. Cell Biochem Funct (2003) 0.83
Acute morphine induces matrix metalloproteinase-9 up-regulation in primary sensory neurons to mask opioid-induced analgesia in mice. Mol Pain (2012) 0.79
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. Nat Cell Biol (2016) 1.00
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun (2014) 0.90
MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development (2017) 0.75